FDA-Drug2026-03-11Class IIPROCESSING DEFECT
Teva Metoprolol Succinate Extended-Release 25 mg tablets recalled for failed dissolution
What this means
Teva Pharmaceuticals is recalling specific lots of Metoprolol Succinate Extended-Release 25 mg tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication properly in your body. This could result in the drug not working as intended. No injuries have been reported.
- Check if your metoprolol bottles match the recalled lot numbers and expiration dates listed in the recall notice
- Contact your pharmacy or doctor if you have one of the affected bottles
- Do not stop taking metoprolol without talking to your doctor first—this is a heart medication
- Your pharmacist can provide a replacement or alternative medication
The agency's original wording
Hazard
Failed Dissolution Specifications
Intended for
Adults
Illnesses reported
None reported
Sold states
Nationwide
Affected count
18,780 bottles
Manufactured in
400 Interpace Pkwy Bldg A, N/A, Parsippany, NJ, United States
Products
Metoprolol Succinate Extended-Release Tablets, 25 mg, 100 tablets bottles (NDC: 45963-709-11) and 1,000 tablets bottles (NDC: 45963-709-96), Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0354-2026More Teva recalls
- FDA-Drug2026-09-09Teva trazodone 50 mg tablets recalled for foreign tablets in bottles
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.